ID: hypothesis-h-2e7eb2ea
Hypothesis

Enteric Nervous System Prion-Like Propagation Blockade

Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve.
🧬 TLR4, SNCA🩺 neurodegeneration🎯 Composite 48%💱 $0.48▲5.3%archived
EvidencePending (0%)📖 24 cit🗣 1 debates 5 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.40 (15%) Evidence 0.50 (15%) Novelty 0.70 (12%) Feasibility 0.30 (12%) Impact 0.60 (12%) Druggability 0.60 (10%) Safety 0.40 (8%) Competition 0.50 (6%) Data Avail. 0.40 (5%) Reproducible 0.40 (5%) KG Connect 0.31 (8%) 0.480 composite

🧪 Overview

Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve. Targeted antimicrobial therapy against specific pathogenic strains could interrupt this ascending pathological cascade.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Dysbiotic Gut<br/>Microbiome"] --> B["Bacterial LPS<br/>Production"]
    B --> C["TLR4 Activation<br/>on Enteric Neurons"]
    C --> D["MyD88 and TRIF<br/>Recruitment"]
    D --> E["NF-kappaB and IRF3<br/>Signaling"]
    E --> F["Pro-inflammatory<br/>Cytokine Release<br/>(IL-1beta, TNF-alpha)"]
    F --> G["Neuroinflammation<br/>in ENS"]
    G --> H["Enhanced alpha-Synuclein<br/>Aggregation"]
    H --> I["Prion-like<br/>alpha-Synuclein<br/>Formation"]
    I --> J["Cell-to-Cell<br/>Transmission<br/>in ENS"]
    J --> K["Vagus Nerve<br/>Propagation"]
    K --> L["CNS alpha-Synuclein<br/>Pathology"]
    L --> M["Neurodegeneration"]
    N["TLR4 Antagonists"] -->|"Therapeutic<br/>Blockade"| C
    O["Microbiome<br/>Restoration"] -->|"Therapeutic<br/>Intervention"| A
    P["Vagotomy"] -->|"Surgical<br/>Intervention"| K

    classDef normal fill:#4fc3f7,color:#0d0d1a
    classDef therapeutic fill:#81c784,color:#0d0d1a
    classDef pathology fill:#ef5350,color:#0d0d1a
    classDef outcome fill:#ffd54f,color:#0d0d1a
    classDef molecular fill:#ce93d8,color:#0d0d1a

    class A,B pathology
    class C,D,E,F,G,H,I,J,K molecular
    class L,M outcome
    class N,O,P therapeutic

⚖️ Evidence

⚖️ Evidence Matrix5 supports2 contradicts
Supports
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Autophagy2022PMID:35287553medium
Supports
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.
Autophagy2022PMID:35000546medium
Supports
Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform.
Autophagy2024PMID:37915239medium
Supports
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
JCI Insight2021PMID:33682798medium
Supports
Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein.
Autophagy Rep2024PMID:40395520medium
Contradicts
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.
Nat Rev Neurol2022PMID:35750883medium
Contradicts
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.
Front Nutr2024PMID:39568727medium
📖 Linked Papers (20)Export BibTeX ↗
Figure 1
Figure 1
Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disea...
Figure 2
Figure 2
Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory med...
Fig. 1
Fig. 1
Neuron-released α-synuclein is engulfed by microglia in vivo. a , b , f , g Brain sections from AAV-GFP ( n  = 768 cells, six animals) and AAV- h α-Syn-inje...
Fig. 2
Fig. 2
Microglia-engulfed α-synuclein is degraded by autophagy. a , b , c Cultured primary microglia from WT mice ( a and left panels of b ) and GFP–LC3-transgeni...
Figures
Figures
Figures available at source paper (no open-access XML found).
Figure 1
Figure 1
Illustration of the protocols, including the time line of the experiments and tests.
Figure 2
Figure 2
LPS-induced memory defects in the MWM test and passive avoidance performance test. ( A ) Mice showed impaired learning and memory function after injections of L...
Figures
Figures
Figures available at source paper (no open-access XML found).
No figures
No figures
The role of the microbiota in glaucoma.
Molecular aspects of medicine (2023) · PubMed:37866106 ↗
No figures
The role of the microbiota in glaucoma.
Molecular aspects of medicine (2023) · PubMed:37866106 ↗
No figures
📙 Related Wiki Pages (15)

🏥 Translation

🧬 3D Protein Structure — TLR4

🧬 PDB 3FXI Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TLR4, SNCA from GTEx v10.

Caudate basal ganglia4.7 Nucleus accumbens basal ganglia4.2 Substantia nigra4.2 Amygdala4.2 Putamen basal ganglia3.9 Cortex3.6median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 44%

0
Active
0
Completed
282
Total Enrolled
PHASE1
Highest Phase
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TLR4, SNCA →

No DepMap CRISPR Chronos data found for TLR4, SNCA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline
2.4 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0603
Events (7d)
0
Price History
▲5.3%

💾 Resource Usage

LLM Tokens
34,972
$0.2158
Total Cost
$0.2158

🔮 Predictions

🔎 Predictions vs Observations3 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
If hypothesis is true, intervention be therapeutically targeted across multiple neurodegenerative conditionsbe therapeutically targeted across multiple neurodegenerative conditions— no observation —pending0.50
If hypothesis is true, intervention be essential for patient stratification and treatment monitoringbe essential for patient stratification and treatment monitoring— no observation —pending0.50
If hypothesis is true, intervention provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneouslyprovide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously— no observation —pending0.50
🔮 Falsifiable Predictions (3)
pendingconf 50%
If hypothesis is true, intervention be essential for patient stratification and treatment monitoring
Predicted outcome: be essential for patient stratification and treatment monitoring
Falsification: Intervention fails to be essential for patient stratification and treatment monitoring
pendingconf 50%
If hypothesis is true, intervention be therapeutically targeted across multiple neurodegenerative conditions
Predicted outcome: be therapeutically targeted across multiple neurodegenerative conditions
Falsification: Intervention fails to be therapeutically targeted across multiple neurodegenerative conditions
pendingconf 50%
If hypothesis is true, intervention provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Predicted outcome: provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Falsification: Intervention fails to provide synergistic neuroprotective effects while addressing multiple pathological mechanisms simultaneously
Related Entities
Metadata
statusproposed
_schema_version1
hypothesis_typeNone
📊 Evidence Profile Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
4325
Outgoing
2684
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.